Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate

Palvella Therapeutics (NASDAQ: PVLA) reported a Q4 loss of $(1.08) per share, missing the analyst consensus estimate of $(0.91) by 18.29%. This represents a significant improvement from the $(5.37) per share loss reported in the same period last year, marking a 79.89% decrease in losses.